This can be explained by the fact that in Boothe et al. [41] all patients were at stage 0–1 and non-metastatic, whereas in Ciftci et al. [43], the positive correlation of the TGF-β1 serum level to survival was observed only in metastatic BC patients. The gene discussed is TGFB1; the disease is breast cancer.